Your search returned 6 studies. (Get alerts for new studies):
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymp
Conditions: Lymphoma, Large-Cell, Diffuse
10 Locations available
- Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma - Lymphoma, Diffuse Large-Cell - Diffuse Large-Cell Lymphoma - Lymphoma
7 Locations available
- A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Systemic Anaplastic Large-Cell Lymphoma - Neoplasms - Anaplastic Lymphoma Kinase, Human - NSCLC
11 Locations available
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Conditions: Acute Myelocytic Leukemia - Acute Lymphocytic Leukemia - Chronic Myelogenous Leukemia - Myelodysplastic Syndrome - Chronic Lymphocytic Leukemia - Marginal Zone Lymphoma - Follicular Lymphomas - Large-cell Lymphoma - Lymphoblastic Lymphoma - Burkitt's Lymp
1 Location available
- Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma - Anaplastic Large-cell Lymphoma
4 Locations available
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lympho
Conditions: Lymphoma, Large-Cell, Anaplastic - Lymphoma, Non-Hodgkin - Lymphoma, T-Cell
22 Locations available
|